MAGNESIUM COMPOSITIONS AND USES THEREOF FOR INCREASING LIFESPAN
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
1 . A method of extending lifespan of a subject comprising administering to said subject an amount of magnesium-containing compound effective to achieve a physiological concentration of magnesium of about 0.75 mM or above, thereby extending the lifespan of said subject, wherein said concentration is measured under a fasting condition.
2 . The method of claim 1 , wherein said concentration of magnesium is measured after fasting for at least about twelve hours.
3 . The method of claim 1 , wherein said physiological concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration.
4 . The method of claim 1 , wherein said magnesium-containing compound is a magnesium-counter ion compound.
5 . The method of claim 4 , wherein said counter ion is an organic counter ion.
6 . The method of claim 5 , wherein said organic counter ion is threonate.
7 . The method of claim 1 , wherein said magnesium-containing compound is a magnesium-supplemented foodstuff.
8 . The method of claim 1 , wherein said concentration is maintained for a period of greater than 1 month.
9 . A method of extending lifespan of a subject comprising administering to a subject an amount of magnesium-containing compound effective to increase a physiological concentration of magnesium by at least about 10% as compared to an initial level of magnesium prior to said administration.
10 . The method of claim 9 , wherein said increase is measured under a fasting condition.
11 . The method of claim 9 , wherein said physiological concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration.
12 . The method of claim 11 , wherein said magnesium-containing compound is a magnesium-counter ion compound.
13 . The method of claim 12 , wherein said counter ion is an organic counter ion.
14 . The method of claim 13 , wherein said organic counter ion is threonate.
15 . The method of claim 14 , wherein said magnesium-containing compound is a magnesium-supplemented foodstuff.
16 . The method of claim 9 , wherein said concentration is maintained for a period of greater than 4 months.
17 . The method of claim 9 , further comprising the step of determining starting physiological magnesium concentration of said subject under a fasting condition.
18 . A method of extending lifespan of a subject comprising administering to a subject an amount of metal-organic counter ion complex effective to increase a physiological concentration of threonate by at least about 10% as compared to an initial level of threonate prior to said administration.
19 . The method of claim 18 , wherein said metal-organic counter ion complex comprises threonate as a counter-ion.
20 . A method of determining an effective amount of magnesium to produce a physiological effect, comprising the steps of:
a. obtaining a sample from a subject being tested, wherein said sample is taken under a fasting condition;
b. determining a physiological concentration of magnesium from said sample; and
c. providing said subject with a magnesium-containing compound dosing regimen effective to achieve a physiological concentration of magnesium of about 0.75 mM or above.
21 . The method of claim 20 , wherein said concentration of magnesium is measured after fasting for at least about twelve hours.
22 . The method of claim 20 , wherein said physiological concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration.
23 . The method of claim 20 , wherein said magnesium-containing compound is a magnesium-counter ion compound.
24 . The method of claim 20 , wherein said counter ion is an organic counter ion.
25 . The method of claim 24 , wherein said organic counter ion is threonate.
26 . The method of claim 20 , wherein said magnesium-containing compound is a magnesium-supplemented foodstuff.
27 . The method of claim 20 , further comprising the step of determining a physiological concentration of magnesium after said subject has begun said dosing regimen.
28 . A method of determining an effective amount of magnesium to produce a physiological effect, comprising the steps of:
a. obtaining a sample from a subject being tested, wherein said sample is taken under a fasting condition;
b. determining a physiological concentration of magnesium from said sample; and
c. providing said subject with a magnesium-containing compound dosing regimen effective to achieve an increase in a physiological concentration of magnesium by at least about 10% as compared to an initial level of magnesium measured under a fasting condition.